MedTrace Logo

Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors

NCT01300468 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2011-02-21

No results posted yet for this study

Summary

The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid tumor patients. Objectives of the study were to determine the maximum tolerated dose and the dose that can be recommended for Phase II investigations.

Conditions

  • Solid Tumour

Interventions

DRUG

PHA-848125AC

Sponsors & Collaborators

  • Nerviano Medical Sciences

    lead INDUSTRY

Principal Investigators

  • Daniel Von Hoff, MD · Scottsdale Clinical Research Institute, Scottsdale AZ, USA

  • Manuel Hidalgo, MD · The Johns Hopkins University, Baltimore MD, USA

  • Daniel Laheru, MD · The Johns Hopkins University, Baltimore MD, USA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2009-05-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01300468 on ClinicalTrials.gov